(1 - 10 von 11
)
TopoTarget gewinnt erfolgreich vollständige Kontrolle über Belinostat...
www.ots.at
- Konsolidierung der weltweiten Produktrechte
Oncology Venture A/S: Oncology Venture enters into financing agreement
www.finanznachrichten.de
Company AnnouncementOncology Venture A/S enters into a financing agreement based on the issuance of convertible notes and warrants Hoersholm, Denmark, November...
Oncology Ventures CEO Peter Buhl Jensen buys shares in the
www.globenewswire.com
Company Announcement Oncology Ventures CEO Peter Buhl Jensen buys shares in the Company Hoersholm, Denmark – December 6, – Oncology Venture A/S...
A match made in Scandinavia - European Biotechnology
european-biotechnology.com
„When I entered the company in as a CEO it seemed to me like a rational model to use MPI's drug response predictor (DRP) technology for developing a propriertary cancer drug pipeline and benefit from the full value the DRP can add a drug,” Peter Buhl Jensen told EuroBiotech. The result was a spin-off dubbed Oncology Venture.
FDA grants Orphan Drug status for belinostat for the treatment of...
www.eqs-news.com
Peter Buhl Jensen further comments 'The PTCL indication is the first step in accordance with our clinical development plan to bring belinostat to the market as fast as possible. At the same time we are pursuing the steps necessary to bring belinostat to the market in larger indications like solid tumors in combination therapy to exploit the ...
MPIs PRP for precision medicine to be studied with Breast Cancer...
www.valuefokus.de
" The objective of the study is to evaluate whether the PRP in practice can predict drug sensitivity to Fulvestrant, epirubicin and vinorelbine + trastuzumab in patients with metastatic breast cancer by comparing the results of the PRPs with the patient's clinical response to a particular drug ", says Adjunct Professor Peter Buhl Jensen, M.D ...
TopoTarget and CuraGen Initiate Phase II Trial of Belinostat (PXD101)...
www.bionity.com
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy...
MPI - Oncology Venture exercises option to inlicense
www.globenewswire.com
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px;...
Oncology Venture appoints new Chief Financial Officer - Cisionnews.cision.com › oncology-venture › oncology-...
news.cision.com
Ulla Hald Buhl, COO and Chief IR & Communications Mobile: + , Or, Peter Buhl Jensen, ...
sortiert nach Relevanz / Datum